News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

First Patient In Cohort 4 Receives Infusion Of Senesco Technologies, Inc. (SNT)’s Therapeutic Candidate, SNS01-T, For The Treatment Of Multiple Myeloma And Non-Hodgkins Lymphoma In Phase 1b/2a Clinical Trial


1/9/2014 10:18:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI) reported the administration of SNS01-T to the first patient in cohort 4 of its Phase 1b/2a study in multiple myeloma and non-Hodgkins B-cell lymphoma.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES